Compare XP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XP | GKOS |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | Cayman Islands | United States |
| Employees | N/A | 1094 |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 14.0B |
| IPO Year | 2019 | 2015 |
| Metric | XP | GKOS |
|---|---|---|
| Price | $13.12 | $237.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $19.94 | ★ $243.85 |
| AVG Volume (30 Days) | ★ 17.8M | 1.5M |
| Earning Date | 11-16-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $12.83 | $53.82 |
| Revenue Next Year | $11.88 | $28.56 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $13.48 | $93.96 |
| 52 Week High | $32.73 | $255.19 |
| Indicator | XP | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 60.24 |
| Support Level | N/A | $147.72 |
| Resistance Level | $17.12 | $255.19 |
| Average True Range (ATR) | 0.63 | 11.87 |
| MACD | 0.03 | -1.86 |
| Stochastic Oscillator | 4.34 | 48.42 |
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.